- 2004: B.S. (Pharmacy), University of Delhi (New Delhi, India)
- 2009: Ph.D. (Pharmacology), Massachusetts College of Pharmacy and Health Sciences (Boston, MA)
- 2009-2010: Post-doctoral Research Fellow in Dr. Alan Faden's Laboratory (Georgetown University Medical Center, Washington, D.C.)
- 2010-2012: Post-doctoral Research Fellow in Dr. Alan Faden's Laboratory (University of Maryland School of Medicine, Baltimore, MD)
In vivo models of single and repeated traumatic brain Injury (TBI: mice controlled cortical impact, rat fluid percussion), pathogenesis and evaluation of therapeutic approaches against brain trauma induced-cell cycle activation, neurodegeneration, neuroinflammation (microglial and astrocyte activation), and behavioral deficits (sensorimotor, cognition, anxiety and depression).
S.V. Kabadi et al. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. Neurotherapeutics, 2012, 9:405-21.
S.V. Kabadi et al. Cyclin D1 gene ablation confers neuroprotection in traumatic brain injury. J Neurotrauma, 2012, 29:813-27.
S.V. Kabadi et al. Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma. J Cereb Blood Flow Metab., 2012, 32:137-49.
S.V. Kabadi et al. Fluid-percussion-induced traumatic brain injury models in rats. Nat. Protocols. 2010, 5:1552-63.
S.V. Kabadi and T.J. Maher. Post-treatment with uridine and melatonin following traumatic brain injury reduces edema formation in various brain regions in rats. Ann. N.Y. Acad. Sci. 2010, 1199: 105-13.
S.V. Kabadi and A. Ally. New and Views: Negative cardiotropism by catestatin and its variants. Endocrinol. 2008, 149:4778-9.
Faculty members: Update your contact information and create a profile.